AbbVie agreed to buy Apogee Therapeutics in a deal valued at $10.9 billion in cash, positioning the pharma company to expand in long-acting immune therapies. The transaction gives AbbVie Apogee’s lead IL-13 program, zumilokibart (an anti–IL-13 therapy) and additional immunology candidates, including development-stage assets aimed at inflammatory diseases. Zumilokibart is designed for infrequent dosing—AbbVie highlighted the potential for administration only a few times per year after initial treatment—targeting multiple indications in atopic dermatitis and asthma. Analysts and investors will focus on whether the long-acting profile can differentiate it against established biologics and small molecules in immune-mediated disease. The acquisition underscores a continued shift toward late-stage immunology platforms where dosing convenience and differentiated mechanisms are increasingly central to market share. For Apogee, the deal provides scale to fund pivotal trials and commercialization planning. For AbbVie, the purchase expands its immunology portfolio with an IL-13 approach that overlaps with competitive arenas across inflammatory bowel disease and dermatology franchises.